<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087438</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0236</org_study_id>
    <secondary_id>CDR0000371578</secondary_id>
    <nct_id>NCT00087438</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I/II Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic body
      radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage
      to normal tissue.

      PURPOSE: This phase II trial is studying how well stereotactic body radiation therapy works
      in treating patients with inoperable stage I or stage II non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine whether treatment with stereotactic body radiotherapy results in acceptable
           local control (i.e., ≥ 80%) in patients with medically inoperable stage I or II
           non-small cell lung cancer.

      Secondary

        -  Determine treatment-related toxicity in patients treated with this therapy.

        -  Determine disease-free survival, overall survival, and patterns of failure in patients
           treated with this therapy.

      OUTLINE: This is a multicenter study.

      Patients receive 3 fractions of stereotactic body radiotherapy over 8-14 days in the absence
      of disease progression or unacceptable toxicity.

      Patients are followed up at 6 and 12 weeks, every 3 months for 2 years, every 6 months for 2
      years, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 52 patients will be accrued for this study within 26 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control at 2 Years</measure>
    <time_frame>From the start of treatment to 2 years</time_frame>
    <description>Local control is defined as absence of local failure, which is defined as the combination of primary tumor failure (PTF) or involved lobe failure (ILF). PTF was defined based on meeting two criteria: 1. Local enlargement defined as ≥ 20% increase in the longest diameter of the gross tumor volume (GTV) per computerized tomography (CT), and 2. Evidence of tumor viability. Tumor viability could be affirmed by either demonstrating positron emission tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, or by repeat biopsy confirming carcinoma. PTF included marginal failures occurring within 1 cm of the planning target volume (PTV). ILF is defined as failure beyond the primary tumor but within the involved lobe. Local control time is defined as time from start of treatment to the the date of local recurrence, last known follow-up (censored), or death without local failure (censored). Rates are estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Specified Adverse Events</measure>
    <time_frame>From randomization to last follow-up. Analysis occurred after all patients had been on study for at least 2 years. Maximum follow-up at time of analysis was 4.2 years.</time_frame>
    <description>Specified adverse events are defined as any treatment-related adverse events that are grade 4, grade 5, or any of the following treatment-related grade 3 adverse events:
Gastrointestinal: dysphagia, esophagitis, esophageal stricture, esophageal ulceration;
Cardiac: pericarditis, pericardial effusion, cardiomyopathy, ventricular dysfunction;
Neurologic: myelitis, neuropathy (cranial and motor)
Hemorrhage: pulmonary or upper respiratory
Pulmonary: decline in pulmonary function as measured by pulmonary function tests, pneumonitis, pulmonary fibrosis, hypoxemia, pleural effusion.
Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The Common Terminology Criteria for Adverse Events (CTCAE) v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Local Recurrence at 2 Years</measure>
    <time_frame>From the start of treatment to 2 years</time_frame>
    <description>Local failure is defined as the combination of primary tumor failure (PTF) or involved lobe failure (ILF). PTF was defined based on meeting two criteria: 1. Local enlargement defined as ≥ 20% increase in the longest diameter of the gross tumor volume (GTV) per computerized tomography (CT), and 2. Evidence of tumor viability. Tumor viability could be affirmed by either demonstrating positron emission tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, or by repeat biopsy confirming carcinoma. PTF included marginal failures occurring within 1 cm of the planning target volume (PTV). ILF is defined as failure beyond the primary tumor but within the involved lobe. Time to local recurrence is defined as time from start of treatment to the the date of local recurrence, last known follow-up (censored), or death without local recurrence (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Regional Recurrence at 2 Years</measure>
    <time_frame>From the start of treatment to 2 years</time_frame>
    <description>Regional recurrence is defined as hilar, mediastinal, and supraclavicular nodal failure.Time to regional recurrence is defined as time from start of treatment to the date of first regional recurrence, last known follow-up (censored), or death without regional recurrence (competing risk). Rates are estimated using the cumulative incidence method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Disseminated Recurrence at 2 Years</measure>
    <time_frame>From the start of treatment to 2 years</time_frame>
    <description>Disseminated recurrence is defined as uninvolved lobe failures and failures beyond the lungs and regional lymph nodes. Time to disseminated recurrence is defined as time from start of treatment to the the date of disseminated recurrence, last known follow-up (censored), or death without disseminated recurrence (competing risk). Rates are estimated using the cumulative incidence method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Disease-free Survival at 2 Years</measure>
    <time_frame>From the start of treatment to 2 years</time_frame>
    <description>Disease is defined as local or regional progression or development of distant metastases. Disease-free survival time is defined as time from start of treatment to the date of disease, death, or last known follow-up (censored). Disease-free survival rates are estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Overall Survival at 2 Years</measure>
    <time_frame>From the start of treatment to 2 years</time_frame>
    <description>Overall survival time is defined as time from start of treatment to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic body radiation therapy (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <arm_group_label>Stereotactic body radiation therapy (SBRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

               -  The following primary cancer subtypes are eligible:

                    -  Squamous cell carcinoma

                    -  Adenocarcinoma

                    -  Large cell carcinoma

                    -  Bronchoalveolar cell carcinoma

                    -  Non-small cell carcinoma not otherwise specified

          -  Stage I or II disease based on 1 of the following tumor node metastasis (TNM) stage
             criteria:

               -  T1, N0, M0

               -  T2 (≤ 5 cm), N0, M0

               -  T3 (≤ 5 cm), N0, M0 (chest wall primary tumors only)

          -  No primary tumor of any T-stage within or touching the zone of the proximal bronchial
             tree* NOTE: *Defined as a volume 2 cm in all directions around the proximal bronchial
             tree (carina, right and left main bronchi, right and left upper lobe bronchi,
             intermedius bronchus, right middle lobe bronchus, lingular bronchus, and right and
             left lower lobe bronchi)

          -  No primary T3 tumors involving the central chest (≤ 2 cm toward carina invasion) or
             structures of the mediastinum

          -  Any hilar or mediastinal lymph nodes &gt; 1 cm on CT scan OR demonstrating suspicious
             uptake on positron-emission tomography scan must be biopsied and confirmed negative
             for NSCLC

          -  The primary tumor must be deemed technically resectable with a reasonable possibility
             of obtaining a gross total resection with negative margins (defined as a potentially
             curative resection (PCR))

          -  Deemed medically inoperable based on pulmonary function for surgical resection of
             NSCLC secondary to an underlying physiological problem, including any of the following
             medical conditions*:

               -  Baseline forced expiratory volume (FEV)_1&lt; 40% of predicted

               -  Postoperative predicted FEV_1 &lt; 30% of predicted

               -  Severely reduced diffusion capacity

               -  Baseline hypoxemia and/or hypercapnia

               -  Exercise oxygen consumption &lt; 50% of predicted

               -  Severe pulmonary hypertension

               -  Diabetes mellitus with severe end organ damage

               -  Severe cerebral, cardiac, or peripheral vascular disease

               -  Severe chronic heart disease NOTE: *Patients who refuse a PCR due to preference,
                  ideology, emotional or psychological issues, mental illness, or inability to give
                  informed consent are not eligible

          -  No evidence of regional or distant metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Cardiovascular

          -  See Disease Characteristics

          -  No active pericardial infection

        Pulmonary

          -  See Disease Characteristics

          -  No active pulmonary infection

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active systemic infection

          -  No other concurrent illness that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent biologic therapy

          -  No concurrent vaccine therapy

        Chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior lung or mediastinal radiotherapy

          -  No concurrent standard fractionated radiotherapy

          -  No concurrent intensity modulated radiotherapy

          -  No concurrent cobalt-60 or charged particle beams (including electrons, protons, or
             heavier ions)

        Surgery

          -  See Disease Characteristics

          -  No concurrent surgery

        Other

          -  No other concurrent antineoplastic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D. Timmerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, Senan S. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable Stage I-II non-small-cell lung cancer. In reply to Dr. Xiao et al. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):318; author reply 318. doi: 10.1016/j.ijrobp.2009.05.050.</citation>
    <PMID>19695451</PMID>
  </reference>
  <reference>
    <citation>Timmerman R, Galvin J, Michalski J, Straube W, Ibbott G, Martin E, Abdulrahman R, Swann S, Fowler J, Choy H. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol. 2006;45(7):779-86. Review.</citation>
    <PMID>16982540</PMID>
  </reference>
  <results_reference>
    <citation>Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010 Mar 17;303(11):1070-6. doi: 10.1001/jama.2010.261.</citation>
    <PMID>20233825</PMID>
  </results_reference>
  <results_reference>
    <citation>Xiao Y, Papiez L, Paulus R, Timmerman R, Straube WL, Bosch WR, Michalski J, Galvin JM. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1235-42. doi: 10.1016/j.ijrobp.2008.11.019.</citation>
    <PMID>19251095</PMID>
  </results_reference>
  <results_reference>
    <citation>Timmerman RD, Paulus R, Galvin J, et al.: Toxicity analysis of RTOG 0236 using stereotactic body radiation therapy to treat medically inoperable early stage lung cancer patients. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-151, S86, 2007.</citation>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <results_first_submitted>February 25, 2014</results_first_submitted>
  <results_first_submitted_qc>February 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2014</results_first_posted>
  <last_update_submitted>December 21, 2018</last_update_submitted>
  <last_update_submitted_qc>December 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stereotactic Body Radiation Therapy (SBRT)</title>
          <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
stereotactic body radiation therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55">Subjects contributing data to the primary analysis are considered to have completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible / No protocol treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible patients who received protocol treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Stereotactic Body Radiation Therapy (SBRT)</title>
          <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
stereotactic body radiation therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="48" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Control at 2 Years</title>
        <description>Local control is defined as absence of local failure, which is defined as the combination of primary tumor failure (PTF) or involved lobe failure (ILF). PTF was defined based on meeting two criteria: 1. Local enlargement defined as ≥ 20% increase in the longest diameter of the gross tumor volume (GTV) per computerized tomography (CT), and 2. Evidence of tumor viability. Tumor viability could be affirmed by either demonstrating positron emission tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, or by repeat biopsy confirming carcinoma. PTF included marginal failures occurring within 1 cm of the planning target volume (PTV). ILF is defined as failure beyond the primary tumor but within the involved lobe. Local control time is defined as time from start of treatment to the the date of local recurrence, last known follow-up (censored), or death without local failure (censored). Rates are estimated using the Kaplan-Meier method.</description>
        <time_frame>From the start of treatment to 2 years</time_frame>
        <population>Eligible patients who started protocol treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy (SBRT)</title>
            <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
stereotactic body radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Local Control at 2 Years</title>
          <description>Local control is defined as absence of local failure, which is defined as the combination of primary tumor failure (PTF) or involved lobe failure (ILF). PTF was defined based on meeting two criteria: 1. Local enlargement defined as ≥ 20% increase in the longest diameter of the gross tumor volume (GTV) per computerized tomography (CT), and 2. Evidence of tumor viability. Tumor viability could be affirmed by either demonstrating positron emission tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, or by repeat biopsy confirming carcinoma. PTF included marginal failures occurring within 1 cm of the planning target volume (PTV). ILF is defined as failure beyond the primary tumor but within the involved lobe. Local control time is defined as time from start of treatment to the the date of local recurrence, last known follow-up (censored), or death without local failure (censored). Rates are estimated using the Kaplan-Meier method.</description>
          <population>Eligible patients who started protocol treatment.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="84.3" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis = 60% two-year local control (0.02128/mo. hazard rate); alternative = 80% (0.0093/mo.) assuming at least approximately exponential distribution of time to local progression. Using the asymptotic properties of the ratio of the logarithms of hazard rates, less than 18 cases of local progression were required for a Type I error rate of 0.05 with 80% power to detect a difference in local control rates at least this large. Hazard rate estimated using life table two-year estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>Test statistic = [ln(estimated hazard rate) - ln(hypothesized hazard rates)] / [1/square root (number of patients with local progression by two years]. Reject null hypothesis at an alpha level of 0.05 if test statistics is less than -1.645.</p_value_desc>
            <method>z-test, one-sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Specified Adverse Events</title>
        <description>Specified adverse events are defined as any treatment-related adverse events that are grade 4, grade 5, or any of the following treatment-related grade 3 adverse events:
Gastrointestinal: dysphagia, esophagitis, esophageal stricture, esophageal ulceration;
Cardiac: pericarditis, pericardial effusion, cardiomyopathy, ventricular dysfunction;
Neurologic: myelitis, neuropathy (cranial and motor)
Hemorrhage: pulmonary or upper respiratory
Pulmonary: decline in pulmonary function as measured by pulmonary function tests, pneumonitis, pulmonary fibrosis, hypoxemia, pleural effusion.
Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The Common Terminology Criteria for Adverse Events (CTCAE) v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.</description>
        <time_frame>From randomization to last follow-up. Analysis occurred after all patients had been on study for at least 2 years. Maximum follow-up at time of analysis was 4.2 years.</time_frame>
        <population>All eligible patients who started study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy (SBRT)</title>
            <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy stereotactic body radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Specified Adverse Events</title>
          <description>Specified adverse events are defined as any treatment-related adverse events that are grade 4, grade 5, or any of the following treatment-related grade 3 adverse events:
Gastrointestinal: dysphagia, esophagitis, esophageal stricture, esophageal ulceration;
Cardiac: pericarditis, pericardial effusion, cardiomyopathy, ventricular dysfunction;
Neurologic: myelitis, neuropathy (cranial and motor)
Hemorrhage: pulmonary or upper respiratory
Pulmonary: decline in pulmonary function as measured by pulmonary function tests, pneumonitis, pulmonary fibrosis, hypoxemia, pleural effusion.
Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The Common Terminology Criteria for Adverse Events (CTCAE) v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.</description>
          <population>All eligible patients who started study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Local Recurrence at 2 Years</title>
        <description>Local failure is defined as the combination of primary tumor failure (PTF) or involved lobe failure (ILF). PTF was defined based on meeting two criteria: 1. Local enlargement defined as ≥ 20% increase in the longest diameter of the gross tumor volume (GTV) per computerized tomography (CT), and 2. Evidence of tumor viability. Tumor viability could be affirmed by either demonstrating positron emission tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, or by repeat biopsy confirming carcinoma. PTF included marginal failures occurring within 1 cm of the planning target volume (PTV). ILF is defined as failure beyond the primary tumor but within the involved lobe. Time to local recurrence is defined as time from start of treatment to the the date of local recurrence, last known follow-up (censored), or death without local recurrence (censored).</description>
        <time_frame>From the start of treatment to 2 years</time_frame>
        <population>Eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy (SBRT)</title>
            <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Local Recurrence at 2 Years</title>
          <description>Local failure is defined as the combination of primary tumor failure (PTF) or involved lobe failure (ILF). PTF was defined based on meeting two criteria: 1. Local enlargement defined as ≥ 20% increase in the longest diameter of the gross tumor volume (GTV) per computerized tomography (CT), and 2. Evidence of tumor viability. Tumor viability could be affirmed by either demonstrating positron emission tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, or by repeat biopsy confirming carcinoma. PTF included marginal failures occurring within 1 cm of the planning target volume (PTV). ILF is defined as failure beyond the primary tumor but within the involved lobe. Time to local recurrence is defined as time from start of treatment to the the date of local recurrence, last known follow-up (censored), or death without local recurrence (censored).</description>
          <population>Eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.3" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Regional Recurrence at 2 Years</title>
        <description>Regional recurrence is defined as hilar, mediastinal, and supraclavicular nodal failure.Time to regional recurrence is defined as time from start of treatment to the date of first regional recurrence, last known follow-up (censored), or death without regional recurrence (competing risk). Rates are estimated using the cumulative incidence method.</description>
        <time_frame>From the start of treatment to 2 years</time_frame>
        <population>Eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy (SBRT)</title>
            <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Regional Recurrence at 2 Years</title>
          <description>Regional recurrence is defined as hilar, mediastinal, and supraclavicular nodal failure.Time to regional recurrence is defined as time from start of treatment to the date of first regional recurrence, last known follow-up (censored), or death without regional recurrence (competing risk). Rates are estimated using the cumulative incidence method.</description>
          <population>Eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Disseminated Recurrence at 2 Years</title>
        <description>Disseminated recurrence is defined as uninvolved lobe failures and failures beyond the lungs and regional lymph nodes. Time to disseminated recurrence is defined as time from start of treatment to the the date of disseminated recurrence, last known follow-up (censored), or death without disseminated recurrence (competing risk). Rates are estimated using the cumulative incidence method.</description>
        <time_frame>From the start of treatment to 2 years</time_frame>
        <population>Eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy (SBRT)</title>
            <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Disseminated Recurrence at 2 Years</title>
          <description>Disseminated recurrence is defined as uninvolved lobe failures and failures beyond the lungs and regional lymph nodes. Time to disseminated recurrence is defined as time from start of treatment to the the date of disseminated recurrence, last known follow-up (censored), or death without disseminated recurrence (competing risk). Rates are estimated using the cumulative incidence method.</description>
          <population>Eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="5.1" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Disease-free Survival at 2 Years</title>
        <description>Disease is defined as local or regional progression or development of distant metastases. Disease-free survival time is defined as time from start of treatment to the date of disease, death, or last known follow-up (censored). Disease-free survival rates are estimated using the Kaplan-Meier method.</description>
        <time_frame>From the start of treatment to 2 years</time_frame>
        <population>Eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy (SBRT)</title>
            <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Disease-free Survival at 2 Years</title>
          <description>Disease is defined as local or regional progression or development of distant metastases. Disease-free survival time is defined as time from start of treatment to the date of disease, death, or last known follow-up (censored). Disease-free survival rates are estimated using the Kaplan-Meier method.</description>
          <population>Eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="53.2" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Overall Survival at 2 Years</title>
        <description>Overall survival time is defined as time from start of treatment to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.</description>
        <time_frame>From the start of treatment to 2 years</time_frame>
        <population>Eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy (SBRT)</title>
            <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Overall Survival at 2 Years</title>
          <description>Overall survival time is defined as time from start of treatment to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.</description>
          <population>Eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="58.9" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Subjects experiencing more than one of a given adverse event are counted only once for that adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stereotactic Body Radiation Therapy (SBRT)</title>
          <description>20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
stereotactic body radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac general - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/bone marrow - Other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrop</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fracture NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin ti</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pulmonary function test NOS decreas</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Muscle weakness NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld</name_or_title>
      <organization>Radition Therapy Oncology Group (RTOG)</organization>
      <email>wseiferheld@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

